Design of an illustration of the mode of action of Tremfya/Guselkumab in psoriatic arthritis. Guselkumab is a monoclonal antibody that inhibits the activity of interleukin-23 produced by myeloid dendritic cells. Guselkumab thereby reduces the differentiation and activation of Th17 cells and the consequent recruitment of pro-inflammatory substances such as IL-17/AF, IL-22, TNF-α, and TNF-γ. In addition, it influences the differentiation and activation of monocyte-like cells and acts on TRM memory cells (tissue-resident memory cells) in the skin. These effects reduce the inflammation of the skin and joints and slow down the progression of the disease.
Project details:
Content: 2 illustration
Utilization: Publications online and print
Specifications: DIN A3 (~4000*3000px)
Client: swot / Janssen
The rights of use of the images shown here belong to the client, use is not permitted. The images are protected with watermarks
Effect of interleukin-23 in psoriatic arthritis
